Mindray Announces Second Quarter 2013 Financial Results

PR Newswire

SHENZHEN, China, Aug. 5, 2013 /PRNewswire/ -- Mindray Medical International Limited (MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2013.      

Highlights for Second Quarter 2013

  • Net revenues increased 14.7% year-over-year to $307.2 million. China sales were strong at $147.4 million, representing 27.9% year-over-year growth and 48.0% of the company's total net revenues.
  • International sales were $159.7 million. Both the emerging markets and Western Europe recorded solid revenue performance with mid-teen year-over-year percentage growth.
  • In-vitro diagnostic sales grew 19.5% year-over-year. Reagent sales contributed 36.6% to the segment, up from 34.4% in the same period last year.
  • Non-GAAP operating income grew 15.2% to $73.1 million and non-GAAP net income increased 14.7% to $68.2 million.
  • Net operating cash flow for the quarter strengthened to $76.2 million, representing an increase of 24.3% from the same period last year, mainly as a result of improved working capital management.
  • The cash conversion cycle was 85 days, compared to 97 days in the same period last year, primarily due to better control on receivable collections.
  • In July, the company completed the acquisition of ZONARE, a U.S. high-end ultrasound technology provider.

"In the second quarter, our strong China sales continued to drive our top-line performance and we are pleased that our sales in the emerging markets improved sequentially. Western Europe revenues remained solid despite the region's economic weakness. Sales in North America were weak this quarter, primarily as a result of tough comparison over last year," said Mr. Li Xiting, Mindray's President and Co-Chief Executive Officer. "We further enhanced our efficiency with better management of our cash conversion cycle. We are also very excited about our recent acquisition of ZONARE, which greatly strengthened our ultrasound R&D capabilities and expanded our high-end product portfolio."

SUMMARY – Second quarter 2013

(in $ millions, except per-share data)

Three Months Ended

              June 30

2013

2012

% chg

Net Revenues

307.2

267.8

14.7%

     Net Revenues Generated in China

147.4

115.3

27.9%

     Net Revenues Generated in International Markets

159.7

152.5

4.7%

Gross Profit

176.5

153.6

14.9%

Non-GAAP Gross Profit

178.7

154.8

15.4%

Operating Income

66.7

55.9

19.4%

Non-GAAP Operating Income

73.1

63.5

15.2%

EBITDA

78.9

66.4

18.8%

Net Income

62.1

52.0

19.3%

Non-GAAP Net Income

68.2

59.5

14.7%

Diluted EPS

0.51

0.44

17.9%

Non-GAAP Diluted EPS

0.56

0.50

13.4%

Net Revenues

Mindray reported net revenues of $307.2 million for the second quarter of 2013, a 14.7% increase from $267.8 million in the second quarter of 2012.

  • Net revenues generated in China increased 27.9% to $147.4 million from $115.3 million in the second quarter of 2012.
  • Net revenues generated in the international markets increased 4.7% to $159.7 million from $152.5 million in the second quarter of 2012.

Performance by Segment

Patient Monitoring & Life Support Products: Net revenues in this segment increased 2.3% to $117.2 million from $114.6 million in the second quarter of 2012, contributing 38.2% to total net revenues in the second quarter of 2013.

In-Vitro Diagnostic Products: Net revenues in this segment increased 19.5% to $88.3 million from $73.9 million in the second quarter of 2012, contributing 28.7% to total net revenues in the second quarter of 2013. Reagents sales represented 36.6% of this segment's net revenues.

Medical Imaging Systems: Net revenues in this segment increased 18.6% to $76.1 million from $64.1 million in the second quarter of 2012, contributing 24.8% to total net revenues in the second quarter of 2013.

Others: Net revenues increased 68.7% to $25.5 million from $15.1 million in the second quarter of 2012, contributing 8.3% to total net revenues in the second quarter of 2013. Other net revenues mainly include sales from the orthopedics business, service revenues from extended warranties, sales of accessories and repair service revenues for post-warranty period.

Gross Margin

Second quarter 2013 gross profit was $176.5 million, a 14.9% increase from $153.6 million in the second quarter of 2012. Second quarter 2013 non-GAAP gross profit was $178.7 million, a 15.4% increase from $154.8 million in the second quarter of 2012. Second quarter 2013 gross margin was 57.5% compared to 57.4% both in the second quarter of 2012 and the first quarter of 2013. Non-GAAP gross margin was 58.2% compared to 57.8% in the second quarter of 2012 and 58.1% in the first quarter of 2013.

Operating Expenses

Selling expenses in the second quarter of 2013 were $54.6 million, or 17.8% of total net revenues, unchanged from the second quarter of 2012 but lower than the 19.5% in the first quarter of 2013. Non-GAAP selling expenses were $52.2 million, or 17.0% of total net revenues, unchanged from the second quarter of 2012 and lower than the 18.5% in the first quarter of 2013.

General and administrative expenses for the second quarter of 2013 were $26.6 million, or 8.7% of total net revenues, compared to 9.7% in the second quarter of 2012 and 11.0% in the first quarter of 2013. Non-GAAP general and administrative expenses for the second quarter of 2013 were $26.0 million, or 8.5% of total net revenues, compared to 8.7% in the second quarter of 2012 and 10.0% in the first quarter of 2013.

Research and development expenses for the second quarter of 2013 were $28.6 million, or 9.3% of total net revenues, compared to 8.9% in the second quarter of 2012 and 10.9% in the first quarter of 2013. Non-GAAP research and development expenses for the second quarter of 2013 were $27.4 million, or 8.9% of total net revenues, compared to 8.4% in the second quarter of 2012 and 10.5% in the first quarter of 2013.

Total share-based compensation expenses, which were allocated to cost of revenues and related operating expenses, were $3.2 million in the second quarter of 2013 compared to $6.0 million in the second quarter of 2012 and $4.8 million in the first quarter of 2013.

Operating income was $66.7 million in the second quarter of 2013, a 19.4% increase from $55.9 million in the second quarter of 2012. Non-GAAP operating income in the second quarter of 2013 was $73.1 million, a 15.2% increase from $63.5 million in the second quarter of 2012. Operating margin was 21.7% in the second quarter of 2013 compared to 20.9% in the second quarter of 2012 and 16.1% in the first quarter of 2013. Non-GAAP operating margin was 23.8% in the second quarter of 2013 compared to 23.7% in the second quarter of 2012 and 19.1% in the first quarter of 2013.

Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA")

Second quarter 2013 EBITDA increased 18.8% year-over-year to $78.9 million from $66.4 million in the second quarter of 2012.

Net Income

Net income increased 19.3% year-over-year to $62.1 million from $52.0 million in the second quarter of 2012. Non-GAAP net income increased 14.7% year-over-year to $68.2 million from $59.5 million in the second quarter of 2012. Net margin was 20.2% in the second quarter of 2013 compared to 19.4% in the second quarter of 2012 and 23.7% in the first quarter of 2013. Non-GAAP net margin was 22.2% in the second quarter of 2013, same with the second quarter of 2012 and compared to 26.7% in the first quarter of 2013.

Second quarter 2013 basic and diluted earnings per share were $0.52 and $0.51 respectively, compared to $0.45 and $0.44 in the second quarter of 2012. Basic and diluted non-GAAP earnings per share were $0.58 and $0.56 respectively, compared to $0.51 and $0.50 in the second quarter of 2012. Shares used in the computation of diluted earnings per share for the second quarter 2013 were 120.8 million.

Other Select Data

Accounts receivable turnover days were 52 days in the second quarter of 2013, improved from 64 days in the second quarter of 2012 and 66 days in the first quarter of 2013. Inventory turnover days were 88 days in the second quarter of 2013, compared to 87 days in the second quarter of 2012 and 103 days in the first quarter of 2013. Accounts payable turnover days were 54 days in the second quarter of 2013, the same with the second quarter of 2012 and compared to 59 days in the first quarter of 2013. Mindray calculates the above working capital turnover days using the average of the beginning and ending net balances of the quarter.

As of June 30, 2013, the company had $958.5 million in cash and cash equivalents as well as short-term investments, compared to $891.0 million as of March 31, 2013. Net cash generated by operating activities and net cash outflow for capital expenditures during the quarter were $76.2 million and $20.2 million respectively.

As of June 30, 2013, the company had around 7,540 employees.

Business Outlook for Full Year 2013

Mindray is raising its full year revenue guidance, expecting at least 18% growth over its full year 2012 net revenues.

The company maintains its full year 2013 non-GAAP net income guidance, expecting at least 15% growth over its non-GAAP net income for the full year of 2012. This guidance excludes any tax benefit related to the National Key Software Enterprise status and assumes a corporate income tax rate of 15% for the Shenzhen subsidiary.

The company expects its capital expenditure for full year 2013 to be around $130 million.

The company's practice is to provide guidance on a full year basis only. This forecast reflects Mindray's current and preliminary views, which are subject to change.

"Looking ahead, we expect China to continue to drive our overall growth and the emerging markets should gradually improve despite continued political and currency challenges in certain countries. As for the developed markets, while we are happy with our performance in Western Europe, we anticipate uncertainty to persist in our North American business," commented Mr. Cheng Minghe, Mindray's Co-Chief Executive Officer and Chief Strategic Officer. "Going forward, we will further enhance our efficiency to strengthen the company's competitive position. On the M&A front, we are confident about the integration of ZONARE and will continue to seek other promising targets and partners."

Conference Call Information

Mindray's management will hold an earnings conference call at 8:00 AM on August 6, 2013 U.S. Eastern Time (8:00 PM on August 6, 2013 Beijing/Hong Kong Time).

Dial-in details for the earnings conference call are as follows:

International Toll Free:


United States:

+1-866-519-4004

Hong Kong:

800-930-346

China Landline:

800-819-0121

 

Local dial-in numbers:


United States:

+1-845-675-0437

Hong Kong:

+852-2475-0994

China Mobile:

400-620-8038

Passcode for all regions:

Mindray

A replay of the conference call may be accessed by phone at the following numbers until August 21, 2013.

U.S. Toll Free:

+1-855-452-5696

International:

+1-646-254-3697

Passcode:

17658491

Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at: http://ir.mindray.com/.

Use of Non-GAAP Financial Measures

Mindray provides gross profit, selling expenses, general and administrative expenses, R&D expenses, operating income, net income and earnings per share on a non-GAAP basis that excludes share-based compensation expense and acquired intangible assets amortization expense, all net of related tax impact, as well as EBITDA to enable investors to better assess the company's operating performance. The non-GAAP measures described by the company are reconciled to the corresponding GAAP measure in the exhibit below titled "Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures".

The company has reported for the second quarter of 2013 and provided guidance for full year 2013 earnings on a non-GAAP basis. Each of the terms as used by the company is defined as follows:

  • Non-GAAP gross profit represents gross profit reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets.
  • Non-GAAP operating income represents operating income reported in accordance with GAAP, adjusted for the effects of share-based compensation, and amortization of acquired intangible assets.
  • Non-GAAP selling expenses represent selling expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation, and amortization of acquired intangible assets.
  • Non-GAAP general and administrative expenses represent general and administrative expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation.
  • Non-GAAP research and development expenses represent research and development expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation.
  • Non-GAAP net income represents net income reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets, all net of related tax impact.
  • Non-GAAP earnings per share represents non-GAAP net income divided by the number of shares used in computing basic and diluted earnings per share in accordance with GAAP, and excludes the impact of the declared dividends for the basic calculation.
  • EBITDA represents net income reported in accordance with GAAP, adjusted for the effect of interest income and expenses, provision of income taxes, depreciation and amortization.

The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three and six months ended June 30, 2012 and 2013, respectively, in the attached financial information.

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including, without limitation, statements about Mindray's anticipated net revenues, non-GAAP net income and capital expenditure for 2013, our assumption of a corporate income tax rate of 15% applicable to the Shenzhen subsidiary, the impact of our recent acquisition of Zonare, our expectation that China is to continue to drive our overall growth and the emerging markets should gradually improve despite continued political and currency challenges in certain countries, our anticipation of uncertainty to persist in our North American business, our optimism about the performance in Western Europe, that we will further enhance our efficiency to strengthen the company's competitive position, that we are confident about the integration of ZONARE and that we will continue to seek other promising targets and partners on the M&A front, are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors, including, without limitation, the growth and expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; our ability to settle disputes with our customers and suppliers; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F which was filed with the Securities and Exchange Commission on April 8, 2013. Our results of operations for the second quarter as of June 30, 2013 are not necessarily indicative of our operating results for any future periods. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.

About Mindray

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems. For more information, please visit http://ir.mindray.com.

For investor and media inquiries, please contact:

In China:
Cathy Gao
Mindray Medical International Limited
Tel: +86-755-8188-8023
Email: cathy.gao@mindray.com

In the U.S:
Hoki Luk
Western Bridge, LLC
Tel: +1-646-808-9150
Email: hoki.luk@westernbridgegroup.com

Exhibit 1

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands)








As of December 31, 2012


As of  Jun 30, 2013



 US$ 


 US$ 



 (Note 1) 


 (unaudited) 

ASSETS




Current assets:





Cash and cash equivalents

247,859


195,373


Restricted cash and restricted investment (Note 2)

21,528


264


Short-term investments 

615,003


763,132


Accounts receivable, net

185,701


183,219


Inventories

110,099


128,150


Value added tax receivables

7,427


19,351


Other receivables

15,704


26,548


Prepayments and deposits

11,081


14,745


Deferred tax assets, net

6,443


8,106

Total current assets

1,220,845


1,338,888







Other assets

10,811


10,844


Accounts receivables, net, non-current

2,172


2,042


Advances for purchase of plant and equipment

3,009


4,641


Property, plant and equipment, net

268,010


285,727


Land use rights, net 

56,921


59,350


Intangible assets, net

132,334


127,754


Goodwill

163,016


170,063

Total assets

1,857,118


1,999,309






LIABILITIES AND SHAREHOLDERS' EQUITY




Current liabilities:





Short-term bank loans

85,100


100,045


Notes payable

8,697


7,983


Accounts payable

53,244


74,992


Advances from customers

17,550


22,581


Salaries payable

69,919


53,313


Other payables

108,528


113,804


Purchase consideration payable

20,354


8,260


Income taxes payable

30,305


18,199


Other taxes payable

8,894


5,067

Total current liabilities

402,591


404,244







Long-term bank loan

50,039


95,013


Other long-term liabilities

4,004


4,088


Deferred tax liabilities, net

23,369


24,255

Total liabilities

480,003


527,600











Shareholders' equity:





Ordinary shares

15


15


Additional paid-in capital

514,280


531,103


Retained earnings

699,992


760,396


Accumulated other comprehensive income

116,556


129,975


Total shareholders' equity

1,330,843


1,421,489






Non-controlling interests

46,272


50,220

Total equity

1,377,115


1,471,709

Total liabilities and equity

1,857,118


1,999,309






(1) Financial information is extracted from the audited financial statements included in the Company's fiscal year 2012 20F.

(2) Restricted cash and restricted investment are mainly those purchase consideration in connection with our acquisition being held on escrow accounts.

Exhibit 2

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars in thousands, except for share and per share data)














   Three months ended Jun 30,


   Six months ended Jun 30,




2012


2013


2012


2013




US$


 US$ 


US$


 US$ 




(unaudited)


 (unaudited) 


(unaudited)


 (unaudited) 


Net revenues










- PRC


115,294


147,415


207,134


258,747


- International 


152,536


159,736


279,713


290,507


Net revenues


267,830


307,151


486,847


549,254


Cost of revenues 


(114,208)


(130,668)


(212,900)


(233,706)


Gross profit


153,622


176,483


273,947


315,548












Selling expenses 


(47,759)


(54,559)


(87,488)


(101,716)


General and administrative expenses 


(26,111)


(26,629)


(45,725)


(53,213)


Research and development expenses 


(23,877)


(28,573)


(48,154)


(54,901)


Income from operations


55,875


66,722


92,580


105,718












Other income, net


388


421


973


499


Interest income


7,260


8,540


15,698


16,227


Interest expense


(1,287)


(1,471)


(1,978)


(2,443)


Income before income taxes and non-controlling interests


62,236


74,212


107,273


120,001


Provision for income taxes


(10,023)


(10,743)


(18,366)


2,191


Net income 


52,213


63,469


88,907


122,192


Less: Net income attributable to non-controlling interests


(206)


(1,419)


(313)


(2,718)


Net income attributable to the Company


52,007


62,050


88,594


119,474












Basic earnings per share


0.45


0.52


0.76


1.01












Diluted earnings per share


0.44


0.51


0.74


0.99












Shares used in the computation of:










Basic earnings per share


116,547,129


118,519,629


116,283,063


118,350,730












Diluted earnings per share


119,394,768


120,779,113


119,353,032


120,909,507

 

Exhibit 3

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)












   Three months ended Jun 30,


   Six months ended Jun 30,



2012


2013


2012


2013



 US$ 


 US$ 


 US$ 


 US$ 



 (unaudited) 


 (unaudited) 


 (unaudited) 


 (unaudited) 


Cash flow from operating activities:









  Net income

52,213


63,469


88,907


122,192


  Adjustments to reconcile net income to net cash provided by operating activities

21,872


17,019


36,280


32,329


  Changes in current assets and liabilities, net of effects of acquisitions

(12,731)


(4,253)


(3,711)


(35,896)


Net cash provided by operating activities 

61,354


76,235


121,476


118,625











Cash flow from investing activities:









   Acquisition cost of subsidiaries, net of cash received 

-


(13,646)


(2,739)


(17,485)


   Capital expenditure

(16,745)


(20,198)


(32,835)


(40,240)


   Decrease in restricted cash and restricted investment 

-


15,865


-


21,264


   Proceeds from sale of short-term investments

-


295,076


144,395


404,337


   Increase in short-term investments and changes in other investing activities

(32,637)


(357,714)


(125,489)


(549,519)


Net cash used in investing activities

(49,382)


(80,617)


(16,668)


(181,643)











Cash flow from financing activities:









   Repayment of bank loans

-


(35,000)


-


(35,000)


   Proceeds from bank loans

2,000


35,000


52,000


95,000


   Dividend paid

-


-


(46,401)


(59,070)


   Proceeds from exercise of options

4,691


2,098


14,138


8,852


   Cash contribution from non-controlling interest

-


-


506


-


Net cash provided by financing activities

6,691


2,098


20,243


9,782











Net increase (decrease) in cash and cash equivalents

18,663


(2,284)


125,051


(53,236)


Cash and cash equivalents, beginning of period

231,010


195,744


124,311


247,859


Effect of exchange rate changes on cash

(1,688)


1,913


(1,377)


750


Cash and cash equivalents, end of period

247,985


195,373


247,985


195,373

 

 

 

Exhibit 4

MINDRAY MEDICAL INTERNATIONAL LIMITED

RECONCILIATONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE

NEAREST COMPARABLE GAAP MEASURES

(Dollars in thousands, except for share and per share data)














   Three months ended Jun 30,


   Six months ended Jun 30,




2012


2013


2012


2013




(unaudited)


(unaudited)


(unaudited)


(unaudited)




 US$ 


 US$ 


 US$ 


 US$ 












Non-GAAP net income attributable to the Company


59,510


68,238


99,894


132,808


Non-GAAP net margin


22.2%


22.2%


20.5%


24.2%


Amortization of acquired intangible assets


(1,629)


(3,202)


(3,264)


(5,804)


Deferred tax impact related to acquired intangible assets


83


209


118


415


Share-based compensation


(5,957)


(3,195)


(8,154)


(7,945)


GAAP net income attributable to the Company


52,007


62,050


88,594


119,474


GAAP net margin


19.4%


20.2%


18.2%


21.8%












Non-GAAP basic earnings per share


0.51


0.58


0.86


1.12


Non-GAAP diluted earnings per share


0.50


0.56


0.84


1.10












GAAP basic earnings per share


0.45


0.52


0.76


1.01


GAAP diluted earnings per share


0.44


0.51


0.74


0.99












 Shares used in computation of: 










 Basic earnings per share 


116,547,129


118,519,629


116,283,063


118,350,730


 Diluted earnings per share 


119,394,768


120,779,113


119,353,032


120,909,507












Non-GAAP operating income


63,461


73,119


103,998


119,467


Non-GAAP operating margin


23.7%


23.8%


21.4%


21.8%


Amortization of acquired intangible assets


(1,629)


(3,202)


(3,264)


(5,804)


Share-based compensation


(5,957)


(3,195)


(8,154)


(7,945)


GAAP operating income


55,875


66,722


92,580


105,718


GAAP operating margin


20.9%


21.7%


19.0%


19.2%












Non-GAAP gross profit


154,796


178,705


276,245


319,419


Non-GAAP gross margin


57.8%


58.2%


56.7%


58.2%


Amortization of acquired intangible assets 


(960)


(2,060)


(1,926)


(3,527)


Share-based compensation


(214)


(162)


(372)


(344)


GAAP gross profit


153,622


176,483


273,947


315,548


GAAP gross margin


57.4%


57.5%


56.3%


57.5%












Non-GAAP selling expenses


(45,472)


(52,191)


(83,838)


(97,097)


Non-GAAP as % of total revenues


17.0%


17.0%


17.2%


17.7%


Amortization of acquired intangible assets 


(669)


(1,142)


(1,338)


(2,277)


Share-based compensation


(1,618)


(1,226)


(2,312)


(2,342)


GAAP selling expenses


(47,759)


(54,559)


(87,488)


(101,716)


GAAP as % of total revenues


17.8%


17.8%


18.0%


18.5%












Non-GAAP general and administrative expenses


(23,317)


(26,023)


(42,418)


(50,181)


Non-GAAP as % of total revenues


8.7%


8.5%


8.7%


9.1%


Share-based compensation


(2,794)


(606)


(3,307)


(3,032)


GAAP general and administrative expenses


(26,111)


(26,629)


(45,725)


(53,213)


GAAP as % of total revenues


9.7%


8.7%


9.4%


9.7%












Non-GAAP research and development expenses


(22,546)


(27,372)


(45,991)


(52,674)


Non-GAAP as % of total revenues


8.4%


8.9%


9.4%


9.6%


Share-based compensation


(1,331)


(1,201)


(2,163)


(2,227)


GAAP research and development expenses


(23,877)


(28,573)


(48,154)


(54,901)


GAAP as % of total revenues


8.9%


9.3%


9.9%


10.0%

Exhibit 5

MINDRAY MEDICAL INTERNATIONAL LIMITED

RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES,

DEPRECIATION AND AMORTIZATION

(Dollars in thousands)














   Three months ended Jun 30,


   Six months ended Jun 30,




2012


2013


2012


2013




US$


US$


US$


US$




(unaudited)


(unaudited)


(unaudited)


(unaudited)











GAAP net income attributable to the Company

$

52,007


62,050


88,594


119,474


Interest income


(7,260)


(8,540)


(15,698)


(16,227)


Interest expense


1,287


1,471


1,978


2,443


Provision for income taxes


10,023


10,743


18,366


(2,191)











Earnings before interest and taxes ("EBIT")


56,057


65,724


93,240


103,499


Depreciation


7,451


7,934


14,041


15,710


Amortization


2,903


5,220


5,792


9,497











Earnings before interest, taxes, depreciation, and amortization ("EBITDA")


66,411


78,878


113,073


128,706

Rates

View Comments (0)